دورية أكاديمية
أعرض في EDS

Insight Into Novel Anti-tuberculosis Vaccines by Using Immunoinformatics Approaches.

التفاصيل البيبلوغرافية
العنوان: Insight Into Novel Anti-tuberculosis Vaccines by Using Immunoinformatics Approaches.
المؤلفون: Khan Z; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangzhou, China.; China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou, China., Ualiyeva D; University of Chinese Academy of Sciences, Beijing, China.; Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China.; Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty, Kazakhstan., Amissah OB; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; University of Chinese Academy of Sciences, Beijing, China., Sapkota S; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangzhou, China.; China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou, China., Hameed HMA; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangzhou, China.; China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou, China., Zhang T; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangzhou, China.; China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou, China.
المصدر: Frontiers in microbiology [Front Microbiol] 2022 Jun 02; Vol. 13, pp. 866873. Date of Electronic Publication: 2022 Jun 02 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101548977 Publication Model: eCollection Cited Medium: Print ISSN: 1664-302X (Print) Linking ISSN: 1664302X NLM ISO Abbreviation: Front Microbiol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Research Foundation
مستخلص: Tuberculosis (TB), an infectious disease, has been a leading cause of morbidity and mortality for decades. The causative agent of TB is the Mycobacterium tuberculosis (Mtb) which can infects various parts of the body, mainly the lungs in pulmonary TB cases. Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is the only approved vaccine for TB, but its efficiency to combat pulmonary TB is limited. Multidrug-resistant (MDR) TB and extensive drug-resistant (XDR) TB requires the evolution of more potent vaccines. Therefore, this research aims to generate a universal TB subunit vaccine using advanced immunoinformatics techniques. In generating a novel multiepitope subunit vaccine, we selected the conserved and experimentally confirmed antigens Rv0058, Rv0101, and Rv3343. After a rigorous evaluation, the top candidates from predicted Helper T-lymphocytes (HTL), Cytotoxic T-lymphocytes (CTL), and B-cell epitopes were considered potential vaccine candidates. Immunogenicity was enhanced by the addition of an adjuvant to the ultimate construct of the vaccine. B-cell epitopes predictions guaranteed the eventual induction of a humoral response. Thereafter, dynamics simulations and molecular docking validated the vaccine-receptor complex's stability and high affinity for the immune receptor TLR-3. Also, immune simulations revealed the significantly elevated levels of immunoglobulins such as IgM, cytokines such as interleukin-2, helper T (Th) cells, and cytotoxic T-cell populations. These results agreed with the actual inflammatory response and showed rapid antigen clearance after manifold exposure. Finally, the E. coli K12 strain was confirmed via in-silico cloning for quality expression. Nevertheless, in vivo experiments should be performed to validate the safety of the proposed vaccine and its inherent ability to prevent TB infection.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Khan, Ualiyeva, Amissah, Sapkota, Hameed and Zhang.)
References: Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W513-8. (PMID: 18515843)
Vaccine. 2014 Oct 14;32(45):5908-17. (PMID: 25218194)
Sci Rep. 2019 Mar 19;9(1):4842. (PMID: 30890730)
Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):259-65. (PMID: 18220946)
Interface Focus. 2015 Feb 6;5(1):20140064. (PMID: 25657842)
F1000Res. 2021 Jan 23;10:44. (PMID: 33841800)
Immunobiology. 2020 May;225(3):151949. (PMID: 32444135)
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W384-8. (PMID: 23737448)
Tuberculosis (Edinb). 2016 Sep;100:118-127. (PMID: 27553419)
Science. 2015 Jun 5;348(6239):1106-12. (PMID: 26045430)
Immunotherapy. 2015;7(9):945-8. (PMID: 26310608)
Amino Acids. 2013 Aug;45(2):257-68. (PMID: 23744401)
PLoS Pathog. 2019 Mar 4;15(3):e1007643. (PMID: 30830940)
J Mol Graph Model. 2017 Nov;78:195-205. (PMID: 29100164)
J Immunol. 2003 Aug 15;171(4):1741-9. (PMID: 12902473)
Pharmaceutics. 2020 Sep 06;12(9):. (PMID: 32899930)
Vaccine. 2019 Aug 23;37(36):5371-5381. (PMID: 31331771)
PLoS Pathog. 2016 Jul 13;12(7):e1005760. (PMID: 27409590)
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W526-31. (PMID: 15215442)
Vaccines (Basel). 2020 Jul 28;8(3):. (PMID: 32731461)
Front Immunol. 2019 Feb 14;10:113. (PMID: 30837982)
Thorax. 2015 Mar;70(3):299-301. (PMID: 25432943)
Scand J Immunol. 2016 Oct;84(4):204-10. (PMID: 27454335)
Expert Opin Biol Ther. 2017 Dec;17(12):1481-1491. (PMID: 28927311)
Sci Rep. 2017 Aug 15;7(1):8285. (PMID: 28811600)
Bioinformatics. 2000 Apr;16(4):404-5. (PMID: 10869041)
J Mol Recognit. 2008 Jul-Aug;21(4):243-55. (PMID: 18496882)
Cancer J. 2011 Sep-Oct;17(5):343-50. (PMID: 21952285)
Vaccine. 2015 Aug 7;33(33):4130-40. (PMID: 26095509)
Proteins. 2003 Feb 15;50(3):437-50. (PMID: 12557186)
J Biochem. 1980 Dec;88(6):1895-8. (PMID: 7462208)
Lancet Respir Med. 2018 Apr;6(4):287-298. (PMID: 29595510)
Nat Rev Immunol. 2017 Feb;17(2):97-111. (PMID: 27748397)
Front Microbiol. 2014 Apr 17;5:172. (PMID: 24860555)
Trends Biochem Sci. 2000 Mar;25(3):147-50. (PMID: 10694887)
Infect Genet Evol. 2020 Sep;83:104357. (PMID: 32438080)
Comput Biol Chem. 2020 Apr;85:107209. (PMID: 32120301)
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W407-10. (PMID: 17517781)
Cell Rep. 2019 Dec 10;29(11):3564-3579.e5. (PMID: 31825836)
PLoS One. 2013 Sep 13;8(9):e73957. (PMID: 24058508)
Am J Respir Crit Care Med. 2019 Jan 15;199(2):220-231. (PMID: 30092143)
Proc Natl Acad Sci U S A. 2004 May 4;101(18):6835-6. (PMID: 15123819)
Microb Pathog. 2020 Mar;140:103937. (PMID: 31862393)
Vaccines (Basel). 2014 Jul 02;2(3):515-36. (PMID: 26344743)
Microb Cell Fact. 2006 Jun 23;5:23. (PMID: 16796731)
PLoS Pathog. 2016 May 31;12(5):e1005667. (PMID: 27244558)
PeerJ. 2020 Jul 27;8:e9572. (PMID: 33194329)
Expert Opin Biol Ther. 2012 Dec;12(12):1601-10. (PMID: 22957516)
Nucleic Acids Res. 2019 Jul 2;47(W1):W322-W330. (PMID: 31106357)
Biotechnol Adv. 2012 Sep-Oct;30(5):1102-7. (PMID: 21968145)
Int Rev Immunol. 2019;38(6):307-322. (PMID: 31478759)
Nat Commun. 2015 Jan 12;6:5829. (PMID: 25581030)
Front Immunol. 2019 May 03;10:934. (PMID: 31130946)
Biol Direct. 2013 Dec 05;8:30. (PMID: 24304645)
Indian J Microbiol. 2020 Mar;60(1):26-36. (PMID: 32089571)
Immunotherapy. 2016 Sep;8(9):987-9. (PMID: 27485072)
Infect Genet Evol. 2017 Apr;49:309-317. (PMID: 28185986)
Infect Genet Evol. 2020 Jun;80:104186. (PMID: 31923726)
Mucosal Immunol. 2020 Jan;13(1):140-148. (PMID: 31636345)
Nat Rev Immunol. 2018 Jan;18(1):46-61. (PMID: 29063907)
Brief Funct Genomics. 2018 Sep 27;17(5):295-307. (PMID: 29982427)
Bioinformatics. 2011 Oct 15;27(20):2843-50. (PMID: 21873636)
Vaccine. 2018 Apr 19;36(17):2262-2272. (PMID: 29571972)
Protein Eng. 2001 Aug;14(8):529-32. (PMID: 11579220)
J Biomol Struct Dyn. 2021 Jul;39(10):3793-3801. (PMID: 32419646)
Bioinformatics. 2017 Oct 01;33(19):3098-3100. (PMID: 28575391)
Curr Pharm Des. 2018;24(11):1157-1173. (PMID: 28914200)
فهرسة مساهمة: Keywords: Mycobacterium tuberculosis; drug resistance; immunoinformatics; therapeutic vaccine; tuberculosis
تواريخ الأحداث: Date Created: 20220620 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9201507
DOI: 10.3389/fmicb.2022.866873
PMID: 35722321
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-302X
DOI:10.3389/fmicb.2022.866873